The authors enrolled 249 patients with suspected bladder cancer to be randomized to Hexvix-assisted transurethral resection of the bladder (TURB) plus single shot mitomycin C (MMC, arm A) or white light TURB plus single shot MMC (arm B). Primary endpoint was recurrence-free survival. 207/249 patients had cancer and 184/207 patients had non-muscle invasive bladder cancer. In 56 patients (30%) MMC was not given due to possible safety concerns after deep TURB. Recurrence rates after 12 months were 18% in arm A and 17% in arm B (p=0.86). The authors concluded that Hexvix-assisted TURB plus single shot MMC is not superior to white light TURB plus single shot MMC.
This trial is possibly biased by the absence of a second TUR and the fact that 30% of patients did not receive MMC. Also, recurrence rates of 17% and 18% imply that patients had a rather good risk profile.
Presented by Tim O'Brien, MA, DM, FRCS, et al. at the 26th Annual European Association of Urology (EAU) Congress - March 18 - 21, 2011 - Austria Centre Vienna, Vienna, Austria
Reported for UroToday by Christian Doehn, MD, PhD, Department of Urology, University of Lübeck Medical School, Lübeck Germany.
View EAU 2011 Annual Meeting Coverage
